Literature DB >> 20823707

Transforming growth factor beta signal transduction: a potential target for maintenance/restoration of transparency of the cornea.

Shizuya Saika1, Osamu Yamanaka, Takayoshi Sumioka, Yuka Okada, Takeshi Miyamoto, Kumi Shirai, Ai Kitano, Sai-ichi Tanaka.   

Abstract

Maintenance of the transparency and regular shape of the cornea are essential to the normal vision, whereas opacification of the tissue impairs vision. Fibrogenic reaction leading to scarring in an injured cornea is characterized by appearance of myofibroblasts, the key player of the fibrogenic reaction, and excess accumulation of fibrous extracellular matrix. Inflammatory/fibrogenic growth factors/cytokines produced by inflammatory cells play a pivotal role in fibrogenic response. Signaling systems involved in myofibroblast formation and fibrogenesis are activated by various growth factors, i.e., transforming growth factor beta or others. Modulation of transforming growth factor beta signal transduction molecules, e.g., Smad and mitogen-activated protein kinases, by gene transfer and other technology provides a new concept of prevention/treatment of unfavorable fibrogenesis in the cornea.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823707     DOI: 10.1097/ICL.0b013e3181eef01c

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  20 in total

1.  Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits.

Authors:  M R Santhiago; V Singh; F L Barbosa; V Agrawal; S E Wilson
Journal:  Exp Eye Res       Date:  2011-09-14       Impact factor: 3.467

2.  Mouse strain variation in SMA(+) myofibroblast development after corneal injury.

Authors:  Vivek Singh; Andre A M Torricelli; Neema Nayeb-Hashemi; Vandana Agrawal; Steven E Wilson
Journal:  Exp Eye Res       Date:  2013-06-18       Impact factor: 3.467

3.  Substratum topography modulates corneal fibroblast to myofibroblast transformation.

Authors:  Kathern E Myrna; Rima Mendonsa; Paul Russell; Simon A Pot; Sara J Liliensiek; James V Jester; Paul F Nealey; Donald Brown; Christopher J Murphy
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

4.  Effect of TGFβ and PDGF-B blockade on corneal myofibroblast development in mice.

Authors:  V Singh; M R Santhiago; F L Barbosa; V Agrawal; N Singh; B K Ambati; S E Wilson
Journal:  Exp Eye Res       Date:  2011-09-29       Impact factor: 3.467

Review 5.  Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency.

Authors:  Steven E Wilson
Journal:  Exp Eye Res       Date:  2012-04-20       Impact factor: 3.467

6.  Tranilast inhibits TGF-β-induced collagen gel contraction mediated by human corneal fibroblasts.

Authors:  Ye Liu; Xiao-Jing Zhao; Xiao-Shuo Zheng; Hui Zheng; Lei Liu; Ling-Bin Meng; Qin Li; Yang Liu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

7.  Transforming growth factor β and platelet-derived growth factor modulation of myofibroblast development from corneal fibroblasts in vitro.

Authors:  Vivek Singh; Flavia L Barbosa; Andre A M Torricelli; Marcony R Santhiago; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-01-12       Impact factor: 3.467

8.  Fibrocyte migration, differentiation and apoptosis during the corneal wound healing response to injury.

Authors:  Luciana Lassance; Gustavo K Marino; Carla S Medeiros; Shanmugapriya Thangavadivel; Steven E Wilson
Journal:  Exp Eye Res       Date:  2018-02-24       Impact factor: 3.467

Review 9.  The corneal fibrosis response to epithelial-stromal injury.

Authors:  Andre A M Torricelli; Abirami Santhanam; Jiahui Wu; Vivek Singh; Steven E Wilson
Journal:  Exp Eye Res       Date:  2016-01       Impact factor: 3.467

10.  Development of ex vivo organ culture models to mimic human corneal scarring.

Authors:  Hélène Janin-Manificat; Marie-Rose Rovère; Stéphane D Galiacy; François Malecaze; David J S Hulmes; Catherine Moali; Odile Damour
Journal:  Mol Vis       Date:  2012-12-01       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.